Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Iran Red Crescent Med J ; 13(3): 187-91, 2011 Mar.
Article in English | MEDLINE | ID: mdl-22737461

ABSTRACT

BACKGROUND: The combination of cisplatin and 5-fluorouracil (PF) is currently considered a standard and effective regimen for the treatment of advanced head and neck carcinomas. The aim of this study was to evaluate the efficacy and safety of docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with unresectable head and neck carcinomas. METHODS: Forty-six patients with previously untreated non-metastatic stage IV head and neck carcinomas were enrolled. All patients received three cycles of induction chemotherapy with docetaxel (75 mg/m(2)), cisplatin (40 mg/m(2)) (days 1-2), and 5-FU (500 mg/m(2), days 1-3), repeated every 21 days. Following induction chemotherapy, all patients underwent concurrent chemoradiotherapy using weekly cisplatin (30 mg/m(2)) and a median total dose of 70 Gy was delivered. Clinical response rate and toxicity were the primary and secondary end-points of the study. RESULTS: There were 31 men and 15 women. All patients had non-metastatic stage IV (T2-3N2-3 or T4N0-3) of disease. Overall and complete response rates were 74% and 24% respectively. Advanced T4 classification was associated with poorer response rate (p value=0.042). The major (grade 3-4) treatment-related toxicities were myelosuppression (78%), anorexia (13%), diarrhea (7%), emesis (11%) and stomatitis/pharyngitis (24%). CONCLUSION: In comparison with the data of historical published trials of the PF regimen, the TPF regimen was more effective. However, the TPF regimen appears to be associated with a higher incidence of major toxicities. Therefore, our limited findings support the TPF regimen as an alternative chemotherapeutic regimen for advanced head and neck carcinomas.

2.
Indian J Med Paediatr Oncol ; 31(4): 105-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21584214

ABSTRACT

BACKGROUND: The purpose of this study was to compare the quality of life (Qol) of female breast cancer survivors who received rehabilitation intervention beside medical care and survivors who received medical care alone. MATERIALS AND METHODS: Fifty-seven female breast cancer survivors were assigned to usual medical care (control group) or to usual medical care plus rehabilitation intervention (experimental group). Qol of all patients was assessed before, 1 week and 3 months after intervention. The intervention consisted of physiotherapy, education and individual counseling. The authors used the European Organization for Research and Treatment of Cancer core questionnaire and breast module (EORTC QLQ-C30/BR23) for the assessment of Qol. RESULTS: Patients who received rehabilitation had significantly better Qol. Overall, mean of Qol scores improved gradually in experimental group from before to 1 week and 3 months after intervention. In contrast, minimal change was observed between pre/post and follow-up measures for control group. CONCLUSION: Rehabilitation after breast cancer treatment has the potential for physical, psychological and overall Qol benefits.

3.
J Laryngol Otol ; 123(1): 114-20, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18588737

ABSTRACT

AIM: To report the characteristics, prognostic factors and treatment outcomes of 102 patients with squamous cell carcinoma of the oral tongue treated and followed up at a single institution over a 25-year period. PATIENTS AND METHODS: This retrospective study was carried out by auditing the medical records of 102 patients diagnosed with squamous cell carcinoma of the oral tongue and treated at our institution between 1982 and 2007. Patient follow up ranged from nine to 310 months (median 35 months). Fifty per cent of the patients were treated with surgery followed by a combination of chemotherapy and radiotherapy (43.1 per cent received concurrent chemoradiation and 6.9 per cent received sequential chemotherapy and radiotherapy), whereas 29.4 per cent received surgery followed by adjuvant radiotherapy alone. The remaining patients (20.6 per cent) did not undergo surgery and were treated with definitive radiotherapy with or without chemotherapy. RESULTS: There were 48 men and 54 women. The age at presentation was 19-85 years (median 57 years). The peak incidence was observed between 60 and 70 years. Resection margins were clear in 75 per cent of patients and involved in 25 per cent. Stage I disease was found in 11.8 per cent of patients, stage II in 34.3 per cent, stage III in 22.5 per cent and stage IV in 31.4 per cent. The five-year disease-free survival and overall survival were 65.7 and 72.5 per cent, respectively. Thirty-five patients suffered recurrence after treatment, 74.0 per cent of them at the site of initial cervical nodal involvement. Univariate analysis for overall survival revealed the following as prognostic factors: treatment schedule (surgical vs non-surgical; p < 0.001); age (<60 years vs >or=60 years; p = 0.038); extent of cervical lymph node involvement (p = 0.015); primary tumour stage (p < 0.001); node stage (p = 0.034); and disease stage (p = 0.013). However, on multivariate analysis, only non-surgical treatment (p = 0.001) and advanced disease stage (p = 0.05) were found to have a negative influence on survival. CONCLUSIONS: Our limited data suggest that, in Iran, squamous cell carcinoma of the oral tongue tends to present at a locally advanced stage, with a high frequency of locoregional failure and a poor outcome. Combined modality therapy should be considered for the majority of patients with squamous cell carcinoma of the tongue.


Subject(s)
Carcinoma, Squamous Cell/therapy , Tongue Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy/statistics & numerical data , Disease-Free Survival , Female , Humans , Iran , Male , Middle Aged , Prognosis , Retrospective Studies , Time Factors , Tongue Neoplasms/pathology , Treatment Outcome , Young Adult
4.
Eur J Cancer Care (Engl) ; 15(5): 497-500, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17177910

ABSTRACT

Although it is quite rare, second primary neoplasms in cancer patients may present with the signs and symptoms of malignant spinal cord compression. Primary spinal cord tumours in the cancer patients may be deceptive and considered as the recurrent first cancer. Therefore, it should be precisely differentiated and appropriately managed. We report such a case of intramedullary ependymoma of the cervical spinal cord mimicking metatstatic recurrent lymphoma and causing cord compression. A 50-year-old man developed intramedullary ependymoma of the cervical spinal cord 1.5 years following chemoradiation for Waldeyer's ring lymphoma. He presented with a 2-month history of neck pain, progressive upper- and lower-extremity numbness and weakness, and bowel and bladder dysfunction. Magnetic resonance imaging revealed an intramedullary expansive lesion extending from C4 to C6 levels of the cervical spinal cord. The clinical and radiological findings were suggestive of malignant process. A comprehensive investigation failed to detect another site of disease. He underwent operation, and the tumour was subtotally resected. The patient's neurological deficits improved subsequently. The development of the intramedullary ependymoma following treating lymphoma has not been reported. We describe the clinical, radiological and pathological findings of this case and review the literature.


Subject(s)
Ependymoma/diagnosis , Neoplasms, Second Primary/diagnosis , Spinal Cord Compression/etiology , Spinal Cord Neoplasms/diagnosis , Cervical Vertebrae , Diagnosis, Differential , Ependymoma/drug therapy , Ependymoma/radiotherapy , Humans , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/radiotherapy , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Oropharyngeal Neoplasms/drug therapy , Oropharyngeal Neoplasms/radiotherapy , Quadriplegia/etiology
5.
Int J Gynecol Cancer ; 16(3): 1101-5, 2006.
Article in English | MEDLINE | ID: mdl-16803492

ABSTRACT

This retrospective analysis aims to report results of patients with cancer of uterine cervix treated with external-beam radiotherapy (EBR) and high-dose rate (HDR) brachytherapy, using manual treatment planning. From 1975 to 1995, 237 patients with FIGO stages IIB-IVA and mean age of 54.31 years were treated. EBR dose to the whole pelvis was 50 Gy in 25 fractions. Brachytherapy with HDR after-loading cobalt source (Cathetron) was performed following EBR completion with a dose of 30 Gy in three weekly fractions of 10 Gy to point A. Survival, local control, and genitourinary and gastrointestinal complications were assessed. In a median follow-up of 60.2 months, the 10-year overall and disease-free survival rate was 62.4%. Local recurrence was seen in 12.2% of patients. Distant metastases to the lymph nodes, peritoneum, lung, liver, and bone occurred in 25.3% of patients. Less than 6% of patients experienced severe genitourinary and/or gastrointestinal toxicity that were relieved by surgical intervention. No treatment-related mortality was seen. This series suggests that 50 Gy to the whole pelvis together with three fractions of 10 Gy to point A with HDR brachytherapy is an effective fractionation schedule in the treatment of locally advanced cancer of cervix. To decrease the complications, newer devices and treatment planning may be beneficial.


Subject(s)
Brachytherapy/methods , Carcinoma/radiotherapy , Cobalt Radioisotopes/therapeutic use , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Brachytherapy/adverse effects , Carcinoma/mortality , Carcinoma/secondary , Cobalt Radioisotopes/adverse effects , Disease-Free Survival , Female , Female Urogenital Diseases/etiology , Gastrointestinal Diseases/etiology , Hemorrhage/etiology , Humans , Middle Aged , Neoplasm Metastasis/diagnosis , Radiation Injuries/epidemiology , Radiotherapy Dosage , Rectovaginal Fistula/etiology , Retrospective Studies , Survival Analysis , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/secondary
6.
J Postgrad Med ; 50(3): 200-1, 2004.
Article in English | MEDLINE | ID: mdl-15377806

ABSTRACT

Radiation-induced sarcoma is a rare complication of radiation therapy. We report a case of radiation-induced chondrosarcoma of the maxilla. An 80-year-old Persian woman developed radiation-induced chondrosarcoma of the left maxilla 7 years after combined chemotherapy and external beam radiation therapy for the Ann Arbor stage IE malignant lymphoma of the right tonsil. She underwent suboptimal tumour resection and died due to extensive locoregional disease 8 months later. An English language literature search of Medline using the terms chondrosarcoma, radiation-induced sarcoma and maxilla revealed only one earlier reported case. We describe the clinical and pathological features of this case and review the literature on radiation-induced sarcomas.


Subject(s)
Chondrosarcoma/etiology , Leukemia, Lymphocytic, Chronic, B-Cell/radiotherapy , Maxillary Neoplasms/etiology , Neoplasms, Radiation-Induced/etiology , Tonsillar Neoplasms/radiotherapy , Aged , Aged, 80 and over , Chondrosarcoma/diagnosis , Chondrosarcoma/surgery , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Maxillary Neoplasms/diagnosis , Maxillary Neoplasms/surgery , Neoplasms, Radiation-Induced/diagnosis , Neoplasms, Radiation-Induced/surgery , Time Factors , Tonsillar Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...